Business Wire

FourKites Launches New Tools and Powerful Enhancements to Increase the Adoption of Supply Chain Visibility and Accelerate Time to Value

1.9.2021 11:00:00 EEST | Business Wire | Press release

Share

FourKites ®, the world’s leading real-time supply chain visibility platform, has released powerful new capabilities designed to help shippers, carriers and forwarders more quickly and easily collaborate to increase end customer satisfaction, reduce supply chain costs and increase on-time delivery performance. With ever-increasing demand, supply chain visibility has become table stakes for modern supply chains, and seamless connection and communication between carriers and shippers has never been more important. FourKites’ combination of swift carrier connections, powerful collaboration tools and the industry’s highest-quality real-time logistics data provides shippers and their forwarder/carrier partners with robust assurances of rapid, frictionless implementation and faster time to value.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210901005371/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

FourKites Launches New Tools and Powerful Enhancements to Increase the Adoption of Supply Chain Visibility and Accelerate Time to Value (Photo: Business Wire)

  • Instant Messenger, now with extended capabilities that allow shippers to chat directly with forwarders and carriers, gives supply chain partners the ability to view and share important information and resolve issues together, in real time. Without leaving the FourKites platform, track-and-trace and dispatch workers, drivers and warehouse personnel can view the critical information that affects shipments and deliveries — all in one single interface. Users can share documents, photographs and notes for any given load, as well as form online workgroups and control access as needed.
  • CarrierLink ®, the industry’s most downloaded visibility app for drivers, now includes improved turn-by-turn navigation for better route optimisation; mobile check-in; and new capabilities for updating appointment times, adding notes to loads and uploading paperwork. It also features enhanced capabilities for viewing fuel stops, weigh stations, location ratings and amenities along routes.

"We have hundreds of carriers within our network, from the courier side to the truckload side. When it comes to onboarding, FourKites has been fantastic,” said Josh Dolan, VP of Global Logistics, Cardinal Health. “They've done a phenomenal job working with carriers through the process and helping us fill the gap with new technologies that simplify and speed up onboarding, and enhance communication between Cardinal Health and our partners."

The German multinational Bayer saves time while increasing customer satisfaction thanks to FourKites’ supply chain visibility platform. The impact has already been so strong that the company has made visibility an essential part of its long term strategy.

“Every day, our carriers automatically share location data with our FourKites platform on hundreds of loads throughout Europe,” says Edmund Jager, Head of Distribution EMEA at Bayer. “We are able to track our products minute by minute and, in real time, pass on detailed arrival times to our customers. This means the distributors we supply always know their stock situation and end customers can depend on us to get them the seeds and crop protection they need, when they need them. We look forward to onboarding more carriers and so strengthen our customer-centric approach.”

In addition, FourKites recently announced its industry-first Tracking Quality Guarantee, which establishes the highest standards in supply chain data, guaranteeing real-time visibility and predictive intelligence into a minimum of 90% of customers’ shipments — end-to-end and across every mode and geography. This differentiated approach gives supply chain partners the collaborative opportunities and network effects they need to improve customer satisfaction and optimise their supply chain performance.

“As the first mover and leading innovator in real-time visibility and supply chain management solutions, FourKites is committed to helping shippers, forwarders and carriers achieve end-to-end supply chain visibility faster, and with assurances of the highest-quality tracking in the industry,” said FourKites founder and CEO Mathew Elenjickal. “We are excited to make these powerful new capabilities available to the community to enable greater collaboration and communication, and ultimately, value.”

About FourKites

FourKites® is the #1 supply chain visibility platform in the world, extending visibility beyond transportation into yards, warehouses, stores and beyond. Tracking more than 2 million shipments daily across road, rail, ocean, air, parcel and courier, and reaching 176 countries, FourKites combines real-time data and powerful machine learning to help companies digitise their end-to-end supply chains. More than 600 of the world’s most recognised brands — including 9 of the top-10 CPG and 18 of the top-20 food and beverage companies — trust FourKites to transform their business and create more agile, efficient and sustainable supply chains. To learn more, visit https://www.fourkites.com/.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Scott Johnston
European PR Lead for FourKites
+31 62 147 8442
scott.johnston@fourkites.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release

Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release

Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release

Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye